A DEA bulk manufacturer notice is not psilocybin legalization

On September 28, 2026, the Drug Enforcement Administration published a one-page notice in the Federal Register: Irvine Labs, Inc., of Huntington Beach, California, has applied to be registered as a bulk manufacturer of several Schedule I controlled substances, including psilocybin and psilocyn.

That sentence is already circulating like a green light.

It is not.

The instrument is a Notice of application — Federal Register Doc 2026-19803, 91 FR 61251, Docket No. DEA-1778; regulations.gov docket DEA-2026-1653 — issued under 21 CFR 1301.33(a). Primary: Federal Register — Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc. (Sep 28, 2026). GovInfo HTML: FR-2026-09-28 / 2026-19803.

An application notice is how DEA tells the public that someone asked for a registration. It is not DEA taking psilocybin off Schedule I. It is not Congress legalizing mushrooms. And it is not a final agency order saying Irvine Labs already holds the registration.

What the notice actually says

DEA records that on August 13, 2026, Irvine Labs applied to bulk-manufacture the following Schedule I substances (drug codes in the notice):

Ibogaine (7260), lysergic acid diethylamide (7315), mescaline (7381), peyote (7415), diethyltryptamine (7434), dimethyltryptamine (7435), psilocybin (7437), and psilocyn (7438).

The company's stated plan is research and development — internally and for distribution to its research customers. The notice closes with a hard line: no other activities for these drug codes are authorized for this registration.

Registered bulk manufacturers of those classes, and other applicants, may file electronic comments or objections — and may request a hearing — on or before November 27, 2026. Electronic comments go through Regulations.gov: comment on DEA-2026-1653-0001.

That is a comment-and-objection window on a proposed registration, not an effective date for a new federal legalization statute.

Three mistakes I keep hearing

"DEA just legalized psilocybin for research labs." Schedule I status did not change in this notice. The substances listed are already Schedule I. The filing is about whether one company gets a bulk manufacturer registration for research work — after the comment period and whatever DEA decides next.

"If a lab can apply, retail is next." The notice authorizes nothing for finished-dosage commercial sale to the public. It does not rewrite state retail rules. It does not turn a smoke-shop SKU sheet into a clinical trial. Treating an FR application notice as a market-open signal is how people burn cash on inventory that still sits under the Controlled Substances Act.

"This is the same thing as the five-tryptamine proposal." It is not. The September 23 NPRM proposing Schedule I for five named tryptamines is a proposed scheduling rule. Yesterday's Irvine Labs page is a registration application notice for substances that are already Schedule I. Different dockets. Different legal work. Do not mash them into one Slack thread labeled "DEA psychedelics update" and rewrite every protocol the same way.

For operators who already tracked Irvine Labs earlier this month: the company also has a separate importer application notice published September 14, 2026 (Doc 2026-18757, Docket DEA-1763), with comments due October 14, 2026. That importer notice includes marihuana, marihuana extract, and tetrahydrocannabinols alongside several of the same psychedelics. Related company news. Still not a deschedule. Still not this September 28 bulk-manufacturer instrument. Primary: Importer application — Irvine Labs (Sep 14, 2026).

What to do before you rewrite the research deck

If you advise clinics, research partners, or brands that sit next to the psychedelic conversation, the next two questions are not the same question.

Did DEA publish a notice that a lab applied, or did DEA publish a final order that the registration was granted?

Does your compliance deck treat "psilocybin research is moving" as "psilocybin is no longer Schedule I," when the September 28 notice still lists psilocybin and psilocyn under Schedule I and limits the company's plan to research customers?

Read Doc 2026-19803. Calendar November 27, 2026 if you have standing to comment or object. Then wait for whatever DEA publishes after that window — approval, denial, or further process — before you tell a client the federal floor moved.

California has been writing psychedelic and cannabis reform for a long time. A Federal Register application notice from a Huntington Beach lab is part of that research story. It is not the end of Schedule I.

If you need help separating research-registration headlines from what is actually controlled today, start here: https://www.thynk.guru/contact-us. When SKU and protocol sheets have to track proposed rules, application notices, and final orders as different animals: https://thynkflow.io. Primary notice: federalregister.gov/documents/2026/09/28/2026-19803.

Disclaimer. This is operator analysis from Thynk Industries, not legal advice, not a lobbying communication, and not a prediction sold as a granted DEA registration. A Federal Register application notice, a trade-press headline, a language model, and a "psilocybin is basically legal for labs now" rumor are not substitutes for counsel reading Doc 2026-19803, Docket No. DEA-1778 (regulations.gov docket DEA-2026-1653), 21 CFR 1301.33, and whatever final DEA action follows the November 27, 2026 comment window.